Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-05-09
2006-05-09
Winkler, Ulrike (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S192100, C424S194100
Reexamination Certificate
active
07041298
ABSTRACT:
The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains an ubiquitin pathway protein binding moiety which recognizes an ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains an ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.
REFERENCES:
patent: 5292638 (1994-03-01), Benz et al.
patent: 6306663 (2001-10-01), Kenten et al.
patent: 6316003 (2001-11-01), Frankel et al.
patent: WO 99/13077 (1999-03-01), None
patent: WO 00/22110 (2000-04-01), None
Skamoto, Kathleen M. et al., “Protacs: Chimeric Molecules that Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation,” PNAS, vol. 98, No. 15, Jul. 17, 2001, pp. 8554-8559.
Gosink, M. and Vierstra, R., “Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes”,Proc. Natl. Acad. Sci., vol. 92, pp. 9117-9121, 1995.
Maniatis, Tom, “A ubiquitin ligase complex essential for the Nf-κB, Wnt/Wingless, and Hedgehog signaling pathways”,Genes&Development., vol. 13, pp. 505-510, 1999.
Weissman, A. “Regulating protein degradation by ubiquitination”,Immunology Today, vol. 18, No. 4, pp. 189-198, 1997.
Yaron, A. et al., “Identification of the receptor component of the IκBα-ubiquitin ligase”,Nature, vol. 396, No. 6711, pp. 590-594, 1998.
Yeh, Ed. et al, “Ubiquitin-like proteins: new wines in new bottles”,Gene, vol. 248, No. 1-2, pp. 1-14, 2000.
Zhou, P. et al, “Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins”,Molecular Cell, vol. 6, pp. 751-756, 2000.
Nawaz, et al., Proteasome-Dependent Degradation of the Human Estrogen Receptor, PNAS 96:1858-1862 (Mar. 1999).
Ivan, M. et al., “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2Sensing”,Science, vol. 292, No. 5516, pp. 464-468, 2001.
Kwon, Y.T. et al., “Bivalent Inhibitor of the N-end Rule Pathway”,J. Biol. Chem., vol. 274, No. 25, pp. 18135-18139, 1999.
Min, J.H. et al., “Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling”,Science, vol. 296, No. 5574, pp. 1886-1889, 2002.
Zheng, N. et al, “Structure of a c-Cbl-UbcH7 Complex: RING Domain Function in Ubiquitin-Protein Ligases”,Cell, vol. 102, No. 4, pp. 533-539, 2000.
Crews Craig
Deshaies Raymond J.
Sakamoto Kathleen M.
California Institute of Technology
DLA Piper Rudnick Gray Cary US LLP
Winkler Ulrike
Yale School of Medicine
LandOfFree
Proteolysis targeting chimeric pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteolysis targeting chimeric pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteolysis targeting chimeric pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638411